Raymond James Financial Services Advisors, Inc. Vaxxinity, Inc. Transaction History

Raymond James Financial Services Advisors, Inc.

  • $69.1 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024
SELL
$0.62 - $0.86 $4,541 - $6,299
-7,325 Reduced 39.61%
11,170 $8,000
Q4 2023

Jan 16, 2024
SELL
$0.7 - $1.31 $114 - $214
-164 Reduced 0.88%
18,495 $15,000
Q3 2023

Oct 24, 2023
BUY
$1.25 - $3.0 $2,072 - $4,974
1,658 Added 9.75%
18,659 $25,000
Q2 2023

Jul 25, 2023
BUY
$1.73 - $2.79 $12,084 - $19,488
6,985 Added 69.74%
17,001 $42,000
Q1 2023

Apr 14, 2023
BUY
$1.43 - $4.24 $14,322 - $42,467
10,016 New
10,016 $22,000

Others Institutions Holding VAXX

# of Institutions
9
Shares Held
469K
Call Options Held
0
Put Options Held
0
View Full List

About Vaxxinity, Inc.

VAXX Quotes by TradingView
  • Ticker VAXX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 112,150,000
  • Market Cap $1.12M
  • Description
  • Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...
More about VAXX
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email